Medicare Enrolled

Dr. Lynn Lang, M.D

Family Medicine · Yuba City, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
1558 POOLE BLVD, Yuba City, CA 95993
5307550882
In practice since 2006 (19 years)
NPI: 1942399050 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Lang from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lang? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Lang

Dr. Lynn Lang is a family medicine specialist in Yuba City, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Lang performed 4,484 Medicare services across 1,158 unique beneficiaries.

Between the years covered by Open Payments, Dr. Lang received a total of $13,757 from 57 pharmaceutical and/or device companies across 773 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in family medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Lang is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 4% volume in CA $13,757 industry payments

Medicare Practice Summary

Medicare Utilization ↗
4,484
Medicare services
Top 4% in CA for family medicine
1,158
Unique beneficiaries
$43
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~236 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 2,220 $18 $32
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
528 $135 $300
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
301 $100 $250
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
285 $11 $100
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
214 $70 $200
Vitamin B-12 injection
An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg.
187 $1 $10
Flu vaccine administration
This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient.
83 $32 $70
Urinalysis, manual
A manual laboratory examination of a urine sample to check for various substances and cells.
82 $3 $30
Flu vaccine, high-dose
High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe.
79 $71 $150
Stool test for blood to screen for colon tumors
A test that analyzes a stool sample to detect hidden blood, which is used to screen for colon tumors.
74 $4 $40
Electrocardiogram (EKG), 12-lead
A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report.
74 $12 $125
Annual wellness visit, follow-up
A follow-up annual wellness visit that includes a personalized prevention plan of service.
74 $135 $250
Steroid injection (triamcinolone)
A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered.
63 $1 $10
Pelvic and clinical breast exam for cancer screening
A physical examination of the pelvis and breasts to screen for cervical or vaginal cancer. This procedure involves a clinical assessment performed by a healthcare provider.
52 $41 $63
Pap smear screening test
A screening test to collect and prepare a cervical or vaginal sample for laboratory analysis.
49 $46 $73
Spirometry test before and after medication
A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication.
40 $33 $145
Pneumococcal conjugate vaccine (PCV20)
An intramuscular injection of the 20-valent pneumococcal conjugate vaccine. It is used to protect against diseases caused by Streptococcus pneumoniae bacteria.
22 $281 $400
Pneumonia vaccine administration
This procedure involves the injection of a vaccine to protect against pneumococcal disease. It is administered by a healthcare provider.
22 $31 $150
Blood glucose test using hand-held instrument
A test that measures the level of sugar in the blood using a portable device. The result helps monitor blood glucose levels.
18 $3 $50
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
17 $42 $150
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$13,757
Total received (2018-2024)
Avg $1,965/year across 7 years
Top 3% in CA for family medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
57
Companies
773
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,713 (99.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$44 (0.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,793
2023
$2,820
2022
$1,592
2021
$2,072
2020
$2,023
2019
$1,940
2018
$1,517

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$572
ABBVIE INC.
$287
AstraZeneca Pharmaceuticals LP
$221
Mylan Specialty L.P.
$112
GlaxoSmithKline, LLC.
$99
Bayer Healthcare Pharmaceuticals Inc.
$69
Otsuka America Pharmaceutical, Inc.
$59
Lilly USA, LLC
$56
PFIZER INC.
$53
Daiichi Sankyo Inc.
$39
Novartis Pharmaceuticals Corporation
$30
Boehringer Ingelheim Pharmaceuticals, Inc.
$29
Merck Sharp & Dohme LLC
$28
Novo Nordisk Inc
$25
SANOFI PASTEUR INC.
$24
Xeris Pharmaceuticals, Inc.
$23
Dexcom, Inc.
$21
Esperion Therapeutics, Inc.
$18
Radius Health, Inc.
$15
Optinose US, Inc.
$13
Top 3 companies account for 60.3% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$2,317
ABBVIE INC.
$1,246
AstraZeneca Pharmaceuticals LP
$1,076
Amarin Pharma Inc.
$802
AbbVie Inc.
$634
GlaxoSmithKline, LLC.
$561
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$492
Boehringer Ingelheim Pharmaceuticals, Inc.
$487
Lilly USA, LLC
$439
Allergan Inc.
$434
Otsuka America Pharmaceutical, Inc.
$427
Novo Nordisk Inc
$421
Janssen Pharmaceuticals, Inc
$360
Corcept Therapeutics
$319
SANOFI-AVENTIS U.S. LLC
$287
Allergan, Inc.
$279
PFIZER INC.
$254
Mylan Specialty L.P.
$236
Takeda Pharmaceuticals U.S.A., Inc.
$220
Sunovion Pharmaceuticals Inc.
$211
ARBOR PHARMACEUTICALS, INC.
$184
Radius Health, Inc.
$163
Medtronic Vascular, Inc.
$159
Novartis Pharmaceuticals Corporation
$112
Merck Sharp & Dohme Corporation
$107
Teva Pharmaceuticals USA, Inc.
$102
Eisai Inc.
$98
SANOFI PASTEUR INC.
$92
Bayer Healthcare Pharmaceuticals Inc.
$85
Xeris Pharmaceuticals, Inc.
$81
Almatica Pharma LLC
$80
Merck Sharp & Dohme LLC
$77
IDORSIA PHARMACEUTICALS US INC
$74
Arbor Pharmaceuticals, Inc.
$72
Esperion Therapeutics, Inc.
$57
Kowa Pharmaceuticals America, Inc.
$56
Biohaven Pharmaceuticals, Inc.
$47
Harmony Biosciences LLC
$46
Biohaven Pharmaceutical Holding Company Ltd.
$43
Abbott Laboratories
$43
Daiichi Sankyo Inc.
$39
Hologic, LLC
$37
Astellas Pharma US Inc
$35
Indivior Inc.
$35
E.R. Squibb & Sons, L.L.C.
$34
Genentech USA, Inc.
$33
Sanofi Pasteur Inc.
$31
Optinose US, Inc.
$30
RedHill Biopharma Inc.
$29
Lundbeck LLC
$25
Grifols USA, LLC
$24
Azurity Pharmaceuticals, Inc.
$24
ARALEZ PHARMACEUTICALS US INC.
$23
Alfasigma USA, Inc.
$21
Dexcom, Inc.
$21
Bausch Health US, LLC
$20
Otsuka Pharmaceutical Development & Commercialization, Inc.
$18
Top 3 companies account for 33.7% of all-time payments
Associated products mentioned in payments ›
ABILIFY MAINTENA · ABILIFY MYCITE · AC2 · ADACEL · AIRSUPRA · AJOVY · ANORO · ANORO ELLIPTA · APLENZIN · Aimovig · Amitiza · Aptima Combo 2 · BELSOMRA · BREZTRI · BREZTRI AEROSPHERE · BYDUREON · CHANTIX · CREON · Dayvigo · Dexcom G6 Transmitter · ELIQUIS · EMGALITY · EUCRISA · EVENITY · EVUSHELD · Edarbi · Edarbyclor · Evekeo ODT · FARXIGA · FASENRA · FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE · FLUZONE HIGH-DOSE · FLUZONE QUADRIVALENT · FORTEO · FreeStyle Libre 2 · GARDASIL · GARDASIL 9 · GATTEX · GLASSIA · GRALISE · GVOKE HYPOPEN · Horizant · INJECTAFER · INVOKANA · JANUVIA · JARDIANCE · Kerendia · Korlym · LEQVIO · LINZESS · LONHALA MAGNAIR · LOREEV XR · LYRICA · Livalo · MENACTRA · MOUNJARO · MYRBETRIQ · Motegrity · Movantik · NEXLETOL · NURTEC ODT · Otezla · Ozempic · PREVNAR 20 · Prolastin-C Liquid · Prolia · QULIPTA · QUVIVIQ · RECORLEV · REXULTI · RYBELSUS · Repatha · Rybelsus · SHINGRIX · SOLIQUA 100/33 · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUBLOCADE · SYMBICORT · Saxenda · TOUJEO · TRELEGY ELLIPTA · TRINTELLIX · TRULICITY · Tresiba · Trintellix · TurboHawk · Tymlos · UBRELVY · Utibron · VIBERZI · VRAYLAR · Vascepa · Victoza · WAKIX · XARELTO · XIFAXAN · Xhance · Xofluza · YUPELRI · Yupelri · ZONTIVITY · Zelnorm
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 3% for family medicine in CA.

Looking for a family medicine specialist in Yuba City?
Compare family medicine physicians in the Yuba City area by procedure volume, costs, and industry payment transparency.
Browse family medicine physicians nearby

Geographic Context

Family medicine physicians within 10 mi
106
Per 100K population
107.1
County median income
$75,450
Nearest hospital
SUTTER SURGICAL HOSPITAL - NORTH VALLEY
5.9 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Lang is a clinical cardiology specialist, with above-average Medicare volume (top 4% in CA), with low-engagement industry engagement in the top 3% of CA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Lang experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Lang performed 2,220 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lang receive payments from pharmaceutical companies?
Yes. Dr. Lang received a total of $13,757 from 57 companies across 773 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lang's costs compare to other family medicine physicians in Yuba City?
Dr. Lang's average Medicare payment per service is $43. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lang) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →